DiaMedica Stock Today

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>DI</div>


1 / 100

Odds of Distress

Analyze Filter   Check how we calculate scores
Equity ratings for DiaMedica Therapeutics are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting January 1, 2020 and ending today March 31, 2020. Click here to learn more.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. DiaMedica Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8 people. more on DiaMedica Therapeutics
DiaMedica Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
DiaMedica Therapeutics SEC Filings
DiaMedica Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameDiaMedica Therapeutics
President CEO, DirectorRick PaulsView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Average Analyst Recommendation
Piotroski F Score
Academic score to determine the current strength of DiaMedica Therapeutics financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
DiaMedica Therapeutics ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Debt to Equity Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Few selected profitability drivers of DiaMedica Therapeutics representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Gross Margin
Profit Margin
DiaMedica Therapeutics (DMAC) is traded on BATS Exchange in USA. It is located in 2 Carlson Parkway and employs 8 people. DiaMedica Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 50.55 M. DiaMedica Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 12.01 M outstanding shares of which 3.66 K shares are currently shorted by private and institutional investors with about 0.05 trading days to cover. The company currently holds about 9.74 M in cash with (9.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check DiaMedica Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

DiaMedica Stock Price Odds Analysis

Odds Down 2.8HorizonTargetOdds Up 2.8
5.32%30 days
Based on normal probability distribution, the odds of DiaMedica Therapeutics to move above current price in 30 days from now is under 95 (This DiaMedica Therapeutics probability density function shows the probability of DiaMedica Therapeutics Stock to fall within a particular range of prices over 30 days) .

DiaMedica Stock Top Holders

DiaMedica Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Manatuck Hill Partners LlcCommon Shares272.4 K1.3 M
Granite Point Capital Management LpCommon Shares227.2 K1.1 M
View DiaMedica Therapeutics Diagnostics

DiaMedica Therapeutics Income Statement Over Time

DiaMedica Therapeutics Income Statement is one of the three primary financial statements used for reporting DiaMedica's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of DiaMedica Therapeutics revenue and expense. DiaMedica Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period. The current year Weighted Average Shares is expected to grow to about 12 M, whereas Consolidated Income is expected to decline to (10.9 M). View More Fundamentals
Consolidated Income    Earning Before Interest and Taxes EBIT    Earning Before Interest and Taxes USD    

DiaMedica Stock Against Markets

Did you try this?

Run Cryptocurrency Center Now


Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

DiaMedica Therapeutics Corporate Filings

DiaMedica Therapeutics SEC Reporting

Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Other Events

DiaMedica Therapeutics Corporate Directors

Michael Giuffre Independent Director
James Parsons Director
Jerry Xiao Director
Continue to Investing Opportunities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page